|
| Press Releases |
|
 |
|
| Monday, September 1, 2025 |
|
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D |
| Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company's total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. more info >> |
|
| Friday, August 15, 2025 |
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC |
| Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the 'Updated Guidelines'). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence. more info >> |
|
| Thursday, August 14, 2025 |
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access |
| Everest Medicines (HKEX 1952.HK, 'Everest') today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY' (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). more info >> |
|
| Friday, August 8, 2025 |
|
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan |
| Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON'. more info >> |
|
| Tuesday, August 5, 2025 |
|
|
NEFECON(R) Receives NMPA Approval for Production Expansion in China, as Everest Medicines Accelerates Accessibility and Capacity Efforts |
| Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON has been officially approved by China's National Medical Products Administration (NMPA). more info >> |
|
| Saturday, August 2, 2025 |
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies |
| Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash. more info >> |
|
| Friday, July 25, 2025 |
|
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million |
| Everest Medicines (HKEX 1952.HK, Everest or the " Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the "Sellers"), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue. more info >> |
|
| Friday, July 4, 2025 |
|
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation |
| Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. more info >> |
|
| Thursday, June 12, 2025 |
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances |
| At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON(budesonide delayed release capsules), the world's first and only approved therapy that directly targets the underlying cause of IgA nephropathy (IgAN), and EVER001, a next-generation covalent reversible BTK inhibitor. more info >> |
|
| Monday, June 9, 2025 |
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025 |
| At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Hong Kong Watch & Clock Fair, Salon de TIME end on a high note
Sept 7, 2025 13:13 HKT/SGT
|
|
|
10th anniversary CENTRESTAGE concludes successfully
Sept 6, 2025 21:36 JST
|
|
|
Mitsubishi Power Receives Contract for Large-Scale GTCC Project with 2,800 MW Total Output for Taiwan's Tung Hsiao Power Plant
Sept 5, 2025 21:47 JST
|
|
|
Hitachi announces historic $1 billion USD manufacturing investment to power America's energy future through production of critical grid infrastructure 
Sept 5, 2025 21:00 JST
|
|
|
Fourth Paradigm announces 2025 interim results
Sept 5, 2025 18:25 HKT/SGT
|
|
|
Asia Unicorn Forum Releases 2024 Report: China, India, Israel Top Asian Unicorn Rankings
Sept 5, 2025 11:03 HKT/SGT
|
|
|
CBL International Reports 1H 2025 Results Highlighting Strong Biofuel Growth, Reduced Net Loss, and Improved Gross Profit Margin
Sept 5, 2025 10:36 HKT/SGT
|
|
|
NEC participates in Locked Shields 2025 hosted by the NATO Cooperative Cyber Defence Centre of Excellence
Sept 5, 2025 11:20 JST
|
|
|
LOLC Advanced Tech and Corsair Group Join Forces to Transform Waste into Fuel in Sri Lanka
Sept 5, 2025 07:00 HKT/SGT
|
|
|
TANAKA Announces Executive Appointment
Sept 5, 2025 3:00 JST
|
|
|
The MOU Signing Ceremony cum Seminar Titled "A New Horizon in Film & TV Trading: Web3 x DMP - Reshaping the Cross-Industry Supply Chain" Hosted by eBRAM Concludes Successfully
Sept 4, 2025 22:35 HKT/SGT
|
|
|
Magnum Opus Resorts Launches International Architectural Design Competition for Iconic Costa Rica Retreat
Sept 4, 2025 21:07 HKT/SGT
|
|
|
U.S. Polo Assn. Celebrates Historic Title Sponsorship of 2025 Pacific Coast Open at Santa Barbara Polo & Racquet Club
Sept 4, 2025 19:00 HKT/SGT
|
|
|
HKTDC Export Confidence Index: 3Q25; Exporter optimism rises as global trade tension falls
Sept 4, 2025 17:10 HKT/SGT
|
|
|
Zhejiang Expressway Absorbs and Merges with Oceanking Development: Establishing Dual A+H Platform to Boost Share Price
Sept 4, 2025 15:02 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
